Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Mish's Global Economic Trend Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Jim McMannis who wrote (40243)	10/31/2005 12:59:34 AM
From: Elroy Jetson	Respond to of 116555

Its a good thing he did write the scrip then, because if he wrote it now no pharmacy has it available for sale. .

To: Jim McMannis who wrote (40243)	10/31/2005 6:33:06 PM
From: Casaubon	Read Replies (3) \| Respond to of 116555

Tamiflu is a minor drug with poor clinical relevance. It was questionable whether it would actually get approval, hence the poor performance until recent hysteria. Exactly why people who are buying consider themselves informed, I'm not quite sure; but I imagine it has something to do with the madness of crowds.

To: Jim McMannis who wrote (40243)	10/31/2005 6:48:50 PM
From: Bucky Katt	Read Replies (1) \| Respond to of 116555

Countries seek to bypass Tamiflu patent Tamiflu is considered one of the few drugs likely to be effective against the spread of bird flu among humans India and two other countries have indicated they may authorise generic production of flu drug Tamiflu without the prior approval of the Swiss producer, Roche. It comes amid growing fears of a bird-flu pandemic. Under World Trade Organisation rules, countries facing a public health emergency can issue licences to legally manufacture generic versions of patented drugs. More>http://www.siliconinvestor.com/readmsg.aspx?msgid=21826592